Targets › LONP1
1 program from 1 company in 2 trials: 2 Phase 2; Neurology, Metabolic and endocrine; next expected readout Oct 2027.
ATP-dependent serine protease that mediates the selective degradation of misfolded, unassembled or oxidatively damaged polypeptides as well as certain short-lived regulatory proteins in the mitochondrial matrix. Endogenous substrates include mitochondrial steroidogenic acute regulatory (StAR) protein, DELE1, helicase Twinkle (TWNK) and the large ribosomal subunit protein MRPL32/bL32m. (UniProt, P36776)
Open in Phaseline: the race on LONP1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pharming Technologies | KL1333 (napazimone) LONP1 activator | LONP1 | Phase 2 | Primary Mitochondrial Disease; Mitochondrial Diseases | Oct 2027 |
Primary Mitochondrial Disease (1) Mitochondrial Diseases (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.